CN
627-18-9
应用筛选条件
关键词:'627-18-9'
显示 1-30 共 47 条结果 关于 "627-18-9" 范围 技术文档
GOAT ANTI-CHOLINE ACETYLTRANSFERASE (ChAT)
Methods (1990) 35:31-37.
7. Soc. Neuroscience Abstracts (1992) Vol 18, pg 1483, #624.2.
8. Brain Research Bulletin (1990) 25:129-137.
9. Brain Research Bulletin (1992) 29:635-642.
10. Neuroscience Letters
Anti-NeuN, clone A60 - Data Sheet
Nature (1996) 383:624-627.
4) J. Neuroscience (1997) 17:5820-5829.
5) J. Neuroscience (1997) 17:7415-7424.
6) J. Neuroscience (1998) 18:3206-3212.
7) J. Neuroscience (1998) 18:5614-5629.
8) J. Neuroscience
Product Information Sheet - T4376
T., Methods in Enzymol., XIX, 273 (1970).
17. Murachi, T. and Kato, J. Biochem., (Tokyo), 62, 627 (1967).
18. Liener, I.E. and Freidenson, B., Methods in Enzymol., XIX, 261 (1970).
19. Arnon, R., Methods
MAK373- Technical Bulletin Final
Patrick, A.K. and Potts, K.E., Protease inhibitors as
antiviral agents. Clin. Microbiol. Rev., 11, 614-627
(1998).
8. Medintz, I., et al., Proteolytic activity monitored by
fluorescence resonance energy
Product Information Sheet - T7254
. Biochem. Biophys., 124, 70, (1968).
17. Murachi, T. and Kato, K.J., Biochem., (Tokyo) 62, 627, (1967).
18. Baird, J.B. and Elmore, D.T., FEBS Lett., 1, 343, (1968).
19. Magnusson, S., Methods in Enzymol
MAK375- Technical Bulletin Final
Patrick, A.K. and Potts, K.E., Protease inhibitors as
antiviral agents. Clin. Microbiol. Rev., 11, 614-627
(1998).
3
8. Medintz, I., et al., Proteolytic
Product Information Sheet - SE120153
in patients with node-negative breast cancer by
DNA flow cytometry. N. Engl. J. Med., 1989;
320:627-33.
4. Elledge, R.M., and McGuire, W.L., Prognostic
factors and therapeutic decisions in axillary
XP725 Antibody Number-Lot Number 071M4826
6 7 8 29 30 31 32 53 54 55 56 77 78 79 80
1.3 9 10 11 12 33 34 35 36 57 58 59 60 81 82 83 84
1.4 13 14 15 16 37 38 39 40 61
Product Information Sheet-3353575910
Dilution Buffer
(Vial 9)
[μL]
Dilution Final
concentration
[fmol/μL]
1 2 Original
(2.5 pmol/μL)
48 1:25 100
2 3 1 7 1:3.3 30
3 2 1 18 1:10 10
4 2 2 18 1:10 3
5 2 3
MILLIPLEX®MAP Human Myokine Panel is an optimized quantitative immunoassay that simultaneously measures 15 novel muscle-secreted factors
21
std
6
18 9 7273 15 123 41 25 87 13 40 23 34 26 124 21
18 11 8366 15 124 42 27 88 14 36 23 35 29 119 22
std
7
Product Information Sheet-11699075001
11 426 338 910
Anti-Fluorescein-POD, Fab fragments, 150 U 11 426 346 910
CDP-Star 1 ml 11 685 627 001
2 x 1 ml 11 759 051 001
Tween 20 50 ml, 5 x 10 ml 11 332 465 001
Article: Virus filtration process development optimization
Antibodies Using Ion
Exchange Membrane Adsorptive Pre-Filtration.
Biotechnol. Bioeng. 106(4) 2010: 627–637.
5 Lit No. RF1013EN00 Rev. B, 11/14 DP SBU-
12-07371: Viresolve® Pro Solution Performance
Guide
Protocol: Rat Bone Panel 3 Kit
ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and
alendronate. Bone 18: 621-627 (1996)
Khosla S and Kleetrkoper M. Biochemical markers of bone turnover. In: Favus
MJ Ed
FlowCellect™ Human T Cell MitoDamage Kit (100 Tests)
to each well
8. Mix the samples thoroughly by pipetting up and down.
9. Incubate the samples for 30 minutes at room temperature (18 to 25ºC) in the dark.
10. Pipette 80 µL of 1X Assay Buffer BA directly
An Update on Ligands for Prostanoid Receptors
The hydantoin BW 245C (Prod. No. B 9305)
has been widely used as a selective DP agonist [18-20]; it
may exist as 9-oxo,11-oxo and 9,11-dioxo tautomers.
Inversion of all chiral centers in the ring systems
Biological Detergents Brochure
220201 61�.9 6-10 1 g
5 g
10 g
25 g
References:
1. Bjellqvist, B., et al. 1982. J. Biochem. Biophys.
Methods 6, 317.
2. Rabilloud, T., et al. 1997. Electrophoresis
JULABO Catalog 2011 en
vol.
liters
Dimensions
W x L x H
cm
9 352 627 FK30-SL -30 ... +200 ±0.005 2 0.46 0.34 0.15 22-26 0.4-0.7 dia.
Fluid flow increases mineralized matrix deposition in 3D perfusion culture of marrow stromal osteoblasts in a dose-dependent manner
. Res. 1, 30–41.
21. Pollack, S. R., Petrov, N., Brankov, G. & Blagoeva, R. (1984) J. Biomech. 17, 627–636.
22. Jacobs, C. R., Yellowley, C. E., Davis, B. R., Zhou, Z., Cimbala, J. M. & Donahue, H. J. (
Reprint: Artifacts of Virus Filter Validation - Best Practices to Maintain the Scaled-Down Model
Antibodies
Using Ion Exchange Membrane Adsorptive
Pre-Filtration. Biotechnol. Bioeng. 106(4) 2010:
627–637.
4 Technical Report #41: Virus Filtration
(Revised 2008). PDA J. Sci. Technol. 62(4)
2008:
Balancing Histone/Protein Acetylation-Gene Regulation and Cancer Therapy
11, 155-161
(2001).
16. Kuo, M.H., et al., Genes Dev., 12, 627-639 (1998).
17. Wang, L., et al., Genes Dev., 12, 640-653 (1998).
18. Grant, P.A., et al., Cell, 94, 45-53 (1998).
19. Grant, P.A.
Magna ChIP™ HT96
hm
en
t
Antibody Performance Using
Magna ChIP HT96 Panel II
1 84 108
133 212
627
1219
1935
0
500
1000
1500
2000
2500
C
on
EZ-Magna ChIP™ HT96 (Cat. No. 17-10078)
hm
en
t
Antibody Performance Using
Magna ChIP HT96 Panel II
1 84 108
133 212
627
1219
1935
0
500
1000
1500
2000
2500
C
on
Magna ChIP™ HT96 (Cat. No. 17-10077)
hm
en
t
Antibody Performance Using
Magna ChIP HT96 Panel II
1 84 108
133 212
627
1219
1935
0
500
1000
1500
2000
2500
C
on
Panorama Human Protein Functional Array-Signal Transduction
BCL2A1 BCL2-related protein A1 597
BDNF brain-derived neurotrophic factor, transcript variant 5 627
BIRC2 baculoviral IAP repeat-containing 2 329
BIRC3 baculoviral IAP repeat-containing protein
Advanced Applications of Engineered Nanomaterials
dispersion in water ��18�9
70 Yb Ytterbium oxide 99.7+% 40-60 nanopowder ��7�00
73 Ta Tantalum 99+% 100 nanopowder 59��8�
74 W Tungsten, activated 99.9+% 100 nanopowder 577�9�
Tungsten(VI) oxide
White Paper - The Message in the Marks: Deciphering Cancer Epigenetics
Ser137) 09-018
Anti-ubiquityl-Histone H2A , clone E6C5 05-678
Histone H2A.X
Anti-Histone H2A.X 07-627
Anti-phospho Histone H2A.X (Tyr142) 07-1590
Anti-phospho-Histone H2A.X (Ser139) , clone JBW301
LC-MS Contaminants: Avoid, identify, mimimize.
115096
LiChrolut® RP-18 E (40 – 63 µm) 500 mg 3 mL
standard PP-tubes 50 extraction tubes per package
119849
Proper mobile phase
preparation to minimize
contaminants
Figure 9.
Combined TICs
Drug Discovery Products & Services - Volume 1, 2014
active 14-654 3 12-550
EGFR, active 14-531 3
EGFR (L858R), active 14-626 3
EGFR (L861Q), active 14-627 3
EGFR (T790M), active 14-725 3
EGFR (T790M, L858R),
active
14-721 3
EphA1, active 14-653 3
Brochure: LC-MS Contaminants
/mm/115333
18 LC-MS Contaminants │ Sample preparation is crucial for minimizing contamination
Hypergrade and gradient grade solvents minimize
contaminant peaks
Figure 9 illustrates the influence
Material Matters Vol. 1, No. 1
et al.
Electroanalysis. �00�, 14(9), 627. (7) Rubio Retama, J. et al. Biosens. Bioelectron.
�004, 20, 1111. (8) Brahim, S. et al. Microchimica Acta �00�, 143, 123. (9)
Abraham, S et al. Biomaterials
1/2